Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide for Metabolism and Ectopic Fat in CKD
NCT05254418Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of dulaglutide in chronic kidney disease (CKD), sponsored by Vanderbilt University Medical Center. Started Mar 2022; status: completed.
02
Drugs
dulaglutide
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05254418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254418.